Mundipharma

29 PBAC submissions on file, active 2005–2024. 62% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Buprenorphine
  Pain · Recommended with restriction · 2021other sponsor
• Pralatrexate
  Oncology · Recommended with restriction · 2017—
• Oxycodone
  Pain · Recommended with restriction · 2019—
• Hydromorphone hydrochloride
  Pain · Recommended · 2018—
• Oxycodone hydrochloride + naloxone hydrochloride
  Pain · Recommended · 2015—
• Buprenorphine with naloxone
  Pain · Not recommended · 2020—
• Buprenorphine/naloxone
  Pain · Recommended with restriction · 2019—
• Fluticasone propionate with eformoterol fumarate
  Respiratory · Recommended · 2013—
• Fluticasone propionate with formoterol fumarate dihydrate
  Respiratory · Not recommended · 2018—
• Fosnetupitant with palonosetron
  Oncology · Recommended with restriction · 2020—
• Leuprorelin
  Endocrinology · Recommended · 2024—
• Leuprorelin acetate
  Endocrinology · Not recommended · 2022other sponsor
• Naloxone
  Pain · Recommended · 2019—
• Netupitant with palonosetron
  Oncology · Recommended with restriction · 2023other sponsor
• Oxycodone hydrochloride and naloxone hydrochloride dihydrate
  Pain · Not recommended · 2010—
• Oxycodone hydrochloride with naloxone hydrochloride dihydrate
  Pain · Recommended with restriction · 2010—
• Oxycodone with naloxone
  Pain · Recommended · 2016—
• Oxycodone, tramadol, codeine, hydromorphone, morphine, tapentadol, buprenorphine, fentanyl
  Pain · Recommended with restriction · 2019—

Therapy area mix

Activity by year

2005 (2) · 2010 (2) · 2013 (1) · 2014 (1) · 2015 (6) · 2016 (4) · 2017 (2) · 2018 (2) · 2019 (5) · 2020 (2) · 2022 (1) · 2024 (1)

Rejection patterns

Across 9 Not recommended decisions on file.

• 1×current restriction level remains appropriate to meet patient needs
• 1×unclear pain treatment algorithm
• 1×risk of prescribing to broader patient population than intended
• 1×quality use of medicines concerns
• 1×potential concern to State and Territories regarding increased opioid access